In a breakthrough for drug discovery, quantum hardware outperformed classical hardware in generating two promising KRAS inhibitors.

In Canada, an impressive roster of machine learning companies and institutions highlights the research being conducted there. However, a paucity of VC funding and few experienced C-suite leaders has stunted the commercialization of great ideas. 

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.